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cme.ctsnetjournals.orgjdoi:10.1016/j.jtcvs.2006.05.064bjective: A paucity of outcome data exists regarding patients with proximal
tomach cancer involving the distal esophagus (Siewert type III tumors). This is
specially true with regard to long-term survival rates after surgical intervention.
ethods: Medical records were reviewed of all patients who underwent total
astrectomy and distal esophagectomy with Roux-en-Y esophagojejunostomy for
iewert type III tumors from January 1975 through December 2000.
esults: There were 116 patients (93 men and 23 women). The median age was 66
ears (range, 22-87 years). Pathologic stage was 0 (carcinoma in situ) in 1 patient,
B in 13 patients, II in 17 patients, IIIA in 34 patients, IIIB in 10 patients, and IV
n 41 patients. Complete resection was achieved in 69 (59.5%) patients. Eleven
9.5%) patients were treated with neoadjuvant therapy, 49 (42.2%) received adju-
ant therapy, and 6 (5.2%) received intraoperative radiation. Follow-up was com-
lete in 114 (98.3%) patients, ranging from 1 to 281 months (median, 14 months).
perative mortality was 5.2%. Complications occurred in 51 (43.9%) patients.
linically significant anastomotic leaks occurred in 15 (12.9%) patients. Median
ospitalization was 13 days (range, 8-70 days). Median follow-up was 14 months
range, 1-281 months). Overall median survival was 434 days, with 1-, 5-, and
0-year survivals of 56.2%, 19.0%, and 13.5%, respectively. The only factor
ssociated with increased hospital mortality was anastomotic leakage (P  .002).
ncomplete resection, increased tumor stage and grade, and splenic involvement
ignificantly worsened long-term survival.
onclusions: Total gastrectomy and distal esophagectomy for Siewert type III
umors is associated with reasonable mortality and significant morbidity. Although
ften palliative, surgical intervention can provide long-term survival, especially in
atients with completely resected, early-stage, low-grade tumors.
 
he prevalence of gastric carcinoma has been decreasing; however, a 
increase in the prevalence of adenocarcinoma of the esophagogastric junc-
tion (AEG) has occurred.1 Unfortunately, inconsistencies in defining tum
ocation have made it difficult to evaluate the results, prognosis, and optimal
reatment strategies for patients with carcinoma in the region of the esophagogastric
unction. To address those issues, a recent consensus report from the International
The Journal of Thoracic and Cardiovascular Surgery ● Volume 132, Number 4 755
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G
TSastric Cancer Association and the International Society for
iseases of the Esophagus has provided a workable defini-
ion of these tumors (Table 1).2
Few comparative data exist for subcardial gastric carci-
oma involving the gastroesophageal junction and distal
sophagus (Siewert type III). This is especially true con-
erning morbidity and long-term mortality after surgical
esection. Although treatment options for these patients
nclude surgical resection, chemotherapy, and radiotherapy
n various types of combinations, the only potentially cur-
tive therapy for these cancers remains surgical resection.
he purpose of this study is to evaluate the outcomes of our
atients with Siewert type III tumors who underwent total
astrectomy with distal esophagectomy to better define the
ole of surgical intervention in this clinical situation.
atients and Methods
ll patients who underwent total gastrectomy and distal esopha-
ectomy with Roux-en-Y esophagojejunostomy for adenocarci-
oma of the proximal stomach involving the distal esophagus
Siewert type III tumors) at our institution between January 1975
nd December 2000 were identified from a prospectively main-
ained surgical database. A dedicated review of pathology, oper-
tive and endoscopic reports, and radiologic studies was under-
aken to ensure that cases included in this study complied with the
efinition of a Siewert type III tumor: adenocarcinoma of the
tomach that infiltrates the esophagogastric junction and distal
sophagus from below with a tumor epicenter within 5 cm of the
ardia.
The medical records of these patients were reviewed for patient
emographics, presenting signs and symptoms, tumor stage (in-
luding T, N, and M status), grade of tumor, surgical approach,
ompleteness of resection, date of surgical intervention, tumor
nvolvement of the spleen or other organs, induction chemotherapy
r radiotherapy, adjuvant chemotherapy or radiotherapy, postop-
rative morbidity and mortality, length of hospitalization, last
ollow-up visit or date of death, disease status at follow-up or
eath, and cause of death.
For the purposes of our analysis, the patients were divided into
groups depending on the date of esophagogastrectomy: the initial
ra (1975-1987) and the latter era (1988-2000). We classified the
rocedures as either complete resection (R0) or incomplete resec-
ion (R1) if microscopic examination of the surgical margins
evealed the presence of residual cancer. Operative mortality in-
luded patients who died within 30 days after the operation or at
ny time during their initial postoperative hospitalization. All
atients were staged with the Union Internationale Contre le Can-
er (UICC) staging system.3 Survival and mortality data we
Abbreviations and Acronyms
AEG  adenocarcinoma of the esophagogastric
junction
UICC Union Internationale Contre le Cancererified with the Social Security Death Index. h
56 The Journal of Thoracic and Cardiovascular Surgery ● OctoDescriptive statistics are reported by using numbers (percent-
ges) for discrete data and medians (ranges) for continuous data.
urvival subsequent to discharge was estimated among the remain-
ng patients who survived hospitalization by using the Kaplan-
eier survival method.4 The association between patient surviv
nd risk factors was examined by using the log-rank test.4,5 The
tudy was reviewed and approved by the Mayo Clinic Institutional
eview Board.
esults
ne hundred sixteen patients were identified: 93 (80.2%)
en and 23 (19.8%) women. Median age at the time of the
peration was 66 years (range, 22-87 years). Signs and
ymptoms were present at the time of diagnosis in 113
97.4%) patients. The most common symptoms were dys-
hagia (60.3%), weight loss (31.0%), pain (15.5%), bleed-
ng (14.7%), and early satiety (12.1%). Thirteen (11.2%)
atients had undergone prior gastric surgery for other pa-
hology, most commonly peptic ulcer disease.
The operative approach was laparotomy alone in 63
54.3%) patients, a left thoracoabdominal approach in 46
39.7%) patients, and laparotomy with a right thoracotomy
n 7 (6.0%) patients. Total or completion gastrectomy and
istal esophagectomy with Roux-en-Y esophagojejunostomy
as performed in all 116 patients. Sixty-nine (59.5%) pa-
ients had complete resections (R0), and 47 (40.5%) had
ncomplete resections (R1), as evidenced by microscopi-
ally positive resection margins. Of the 47 patients with
ositive margins, 5 (10.6%) had positive margins at the
roximal esophageal margin alone. Forty-one (87.2%) had
ositive margins on the stomach or other organ resected en
loc. One (2.1%) patient had both a positive proximal
sophageal margin and distal margin. Positive margins were
ncountered in 28 (44.4%) of the laparotomy-alone ap-
roaches, 16 (34.8%) of the left thoracoabdominal ap-
roaches, and 7 (100%) of the laparotomy and right thora-
otomy approaches.
The median number of lymph nodes resected in the
pecimen was 13 (range, 2-46). In patients classified as
ABLE 1. Classification of adenocarcinoma of the esopha-
ogastric junction*
lassification type Description
I Adenocarcinoma of the distal esophagus
that infiltrates the esophagogastric
junction from above
II Adenocarcinoma of the cardia,
“junctional carcinoma”
III Adenocarcinoma of the stomach that
infiltrates the esophagogastric junction
and distal esophagus from below
Siewert and Stein.2aving N0 disease, 20 (66.7%) had at least 15 lymph nodes
ber 2006
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TSesected. In most cases a D1 lymph node dissection was
ccomplished, often including further dissection of N2 level
odes.
The spleen was removed in 76 (65.5%) patients and was
nvolved by tumor in 19 (25%) patients. Splenectomy was
ore frequent in the earlier era of this series (38/40
95.0%]) compared with in the latter era (38/76 [50.0%]). In
ddition, 28 (24.1%) patients had concomitant resection of
t least one other organ/structure that included the dia-
hragm, pancreas, gall bladder, liver, adrenal, ureter, peri-
ardium, and kidney. All resections and reconstructions
ere completed during the same operation. Patient demo-
raphics and details of the operative procedure and patho-
ABLE 2. Patient characteristics and operative details
haracteristic Median Range
ge (y) 66 22-87
n %
ex
Male 93 80.2
Female 23 19.8
rior gastric surgery
Billroth I 2 1.7
Billroth II 9 7.8
Other 2 1.7
None 103 88.8
rade of adenocarcinoma
2 16 13.8
3 32 27.6
4 68 58.6
urgical approach
Laparotomy alone 63 54.3
Left thoracoabdominal 46 39.7
Laparotomy with right thoracotomy 7 6.0
ompleteness of resection
Complete resection, R0 69 59.5
Incomplete resection, R1 47 40.5
pleen
Splenectomy 76 65.5
Spleen preserved 40 34.5
ear of operation
1975-1987 40 34.5
1988-2000 76 65.5
nduction treatment
Chemotherapy alone 7 6.0
Chemotherapy and Radiotherapy 4 3.5
None 105 90.5
djuvant treatment
Chemotherapy 30 25.9
Radiotherapy 6 5.2
Chemotherapy and radiotherapy 13 11.2
None 67 57.7ogic staging are included in Tables 2 and 3. F
The Journal of Thoracicospital Course
here were no intraoperative deaths. Six patients died
ithin 30 days of resection or during the initial postopera-
ive hospitalization (operative mortality, 5.2%). Cause of
eath was sepsis caused by anastomotic leak in 4 patients
nd stroke and myocardial infarction with stroke in 1 patient
ach. Median hospitalization was 13 days (range, 8-70 days).
ll patients were dismissed on a soft diet and monthly injec-
ions of vitamin B12. Complications occurred in 51 (43.9%)
atients. The 2 most common complications were anasto-
otic leak (12.9%) and atrial fibrillation (11.2%). With
egard to the anastomotic leaks, the operative approach was
aparotomy alone in 7 (11.1%) patients and left thoracoab-
ominal in 8 (17.4%) patients and was not statistically
ifferent. All other complications are listed in Table 4
The only factor predictive of operative mortality was
nastomotic leak (P  .002), with an odds ratio of 18.0
95% CI, 3.0-109.8). Operative mortality was 26.7% in
hose with an anastomotic leak compared with only 2.0% in
hose without a leak.
ong-term Survival
ollow-up was complete in 108 (98.1%) operative survi-
ors. Median follow-up was 14 months (range, 1-281
onths). Overall median survival was 434 days (range, 9
ays-281 months). One-, 5-, 10-, and 15-year survivals were
6.2%, 19.0%, 13.5%, and 12.3%, respectively (Figure
ABLE 3. Pathologic stage of tumor
Stage n %
UICC stage
0 (carcinoma in situ) 1 0.9
IB 13 11.2
II 17 14.7
IIIA 34 29.3
IIIB 10 8.6
IV 41 35.3
T status
T0 1 0.9
T1 1 0.9
T2 29 25.0
T3 54 46.6
T4 31 26.7
N status
N0 30 25.9
N1 55 47.4
N2 21 18.1
N3 10 8.6
M status
M0 101 87.1
M1 15 12.9
ICC, Union Internationale Contre le Cancer; T, tumor metastases; N, lymph
ode metastases; M, distant metastases.ifty-seven (49.1%) patients had 63 recurrences. Of these
and Cardiovascular Surgery ● Volume 132, Number 4 757
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G
TS3 recurrences, 36 (57.1%) were locoregional, 11 (17.5%)
ere anastomotic, and 16 (25.4%) were distant.
Factors found to be significantly associated with long-
erm survival were complete resection (P  .0001), early
ICC stage (P  .0001), early-stage T status (P  .0001),
ow N status (P  .002), low tumor grade (P  .02), and
ack of splenic involvement by tumor (P  0.007). These
esults are summarized in Figures 2 through 4 and Fi
1 through E3. Factors not affecting survival included 
ex, induction therapy, prior gastric surgery, surgical ap-
roach, splenectomy, era of operation, anastomotic leak or
ther postoperative complications, adjuvant therapy, and
1 status.
iscussion
pinions differ regarding the definition and optimal treat-
ent of AEG.6,7 The classification system proposed initial
y Siewert and Stein is useful because it differentiates the
ancers in a way that assists in planning the appropriate
urgical resection.2,8 Type I tumors (see Table 1) are se-
ngly the least controversial and are most commonly treated
y means of esophagectomy with en bloc resection of the
roximal stomach and reconstruction with the stomach as
he replacement conduit. Type II tumors are less well de-
ned in terms of optimal surgical resection, and the optimal
ype of resection depends on whether the tumor extends
roximally, distally, or in both directions.9 If subcardial
able 4. Complications of surgery*
omplication n %
nastomotic leak 15 12.9
trial fibrillation 13 11.2
ound infection 9 7.8
neumonia 6 5.2
ntra-abdominal abscess 5 4.3
rinary retention 4 3.4
nterocutaneous fistula 3 2.6
yocardial infarction 3 2.6
mpyema 3 2.6
troke 2 1.7
ancreatic leak 2 1.7
ancreatitis 2 1.7
espiratory failure 2 1.7
ound dehiscence 2 1.7
leeding requiring reoperation 1 0.9
eep venous thrombosis 1 0.9
ulmonary embolism 1 0.9
telectasis requiring bronchoscopy 1 0.9
mall bowel obstruction requiring
operative intervention
1 0.9
iaphragmatic dehiscence 1 0.9
Some patients experienced more than one complication.astric involvement is minimal, we prefer to treat these s
58 The Journal of Thoracic and Cardiovascular Surgery ● Octos
umors by means of esophagectomy with proximal gastrec-
omy. The goals of treatment are a complete resection with
dequate (5 cm) margins, similar to type I cancers.10 Type
II tumors, despite having a distinct anatomic localization in
he region below the gastric cardia, have not been ap-
roached in a consistent fashion.11 Because these cancer
ave the bulk of their tumor in the proximal stomach, the
ost common procedure has been total gastrectomy with
esection of the distal esophagus and reconstruction with
oux-en-Y esophagojejunostomy to obtain adequate mar-
ins.9 This has been the preferred approach for these tum
t our institution for the last 30 years.
In our earlier experience (1975-1987), en bloc splenec-
omy was also performed in 95% of our patients. It was not
ntil the 1990s that randomized studies demonstrated the
ecreased survival of patients undergoing concomitant sple-
ectomy.12,13 More recently, concomitant splenectomy h
lso been associated with an increase in infectious compli-
ations.14 As a result, splenectomy was not only done 
requently (50%) in our later experience but also more
electively, with 40% of these being performed for direct
plenic involvement by tumor. Today, it is now our practice
o avoid splenectomy in these cases unless it is directly
nvolved by tumor.
Our operative approach varied, with 40% of cases being
one from a left thoracoabdominal incision, whereas the
emaining cases were approached with a laparotomy alone
54%) or a laparotomy and subsequent right thoracotomy
6%). Surgeon preference was the most common determin-
ng factor. The surgical approach was not associated with
ifferences in operative mortality, morbidity, or long-term
urvival.
Anastomotic leaks were the most ominous complication
igure 1. Overall survival (death from any cause). Zero time on
he abscissa represents the date of surgical resection.een in our series, with an operative mortality rate of 26.7%.
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G
TShey were the only independent factor predictive of oper-
tive mortality with an odds ratio of 18.0. The management
f these unfortunate events is clearly an important aspect
f the overall care of patients undergoing this operation.
voidance of anastomotic leaks by means of meticulous
urgical technique is paramount. Furthermore, a high index
f suspicion for the early detection and treatment of this
omplication might also play a significant role in mitigating
he ultimate severity of this injury. As a practice, we have
enerally been very liberal in placing drains at the site of
ur esophagojejunostomy at the time of the initial operation.
f an anastomotic leak is identified, adequate drainage is
ssential, with early primary repair being accomplished if
ossible. The placement of a downstream feeding jejunos-
igure 2. Survival (death from any cause) by completeness of
esection. R0 and R1 denote complete resection and incomplete
esection, respectively. Zero time on the abscissa represents the
ate of surgical resection (P < .0001).
igure 3. Survival (death from any cause) by Union Internationale
ontre le Cancer (UICC) stage. Zero time on the abscissa repre-sents the date of surgical resection (P < .0001).
The Journal of Thoracicomy tube at the time of the initial operation is also helpful
n managing these complications, if they occur.
Although AEG tumors have recently been acknowledged
s a unique clinical entity, few studies have examined type
II tumors as a distinct group; instead, most studies group all
 types together.6,15,16 This might be inappropriate, how-
ver, because type III tumors appear to have a poorer
ong-term survival, with overall 5-year survival of approx-
mately 20% to 25%.8,9,17 Siewert and colleagues9 have
eported a 10-year survival of 17%. Our series with a 1-, 5-,
0-, and 15-year survival of 56%, 19%, 13%, and 12%,
espectively, suggests that despite a rapid decrease in sur-
ival during the first 5 years, a small subset of patients
urvive long term.
Predictors of long-term survival in our series included
ICC stage, T status, N status, and tumor grade. These
esults are relevant in the context of the existing debate over
hether the current staging system provides adequate prog-
ostic information for AEG tumors.2,6,15,16,18 For patients
ith Siewert type III tumors, the UICC staging system for
astric adenocarcinoma would appear to provide useful and
rognostic information. Stage I tumors showed relatively
avorable 1-, 5-, 10-, and 15-year survival rates of 92.3%,
3.8%, 29.9%, and 15.0%, respectively.
Achieving a complete resection was associated with
ignificantly improved long-term survival. There was no
-year survival for patients with positive margins. Clearly,
o avoid a purely palliative yet potentially morbid operation,
pproaches and strategies that improve the ability to achieve
egative surgical margins (R0 resection) are needed and
ight include neoadjuvant therapies.
We identified tumor grade as a prognostic factor for
ong-term survival. Although no other investigators have
igure 4. Survival (death from any cause) by T status. Zero time
n the abscissa represents the date of surgical resection (P <
0002).pecifically looked at the influence of grade on survival in
and Cardiovascular Surgery ● Volume 132, Number 4 759
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G
TSiewert type III cancers, this factor has been found to be
mportant in other studies of early gastric cancer and of
EG tumors that are grouped together.19-21
Prior gastric surgery, induction therapy (including che-
otherapy and radiotherapy), and adjuvant treatments did
ot influence operative mortality or long-term survival in
ur series. Because our series was retrospective and reports
n a relatively small number of patients treated with induc-
ion or adjuvant therapy, we cannot comment on the role of
ither of these treatment adjuncts for Siewert type III tu-
ors. Nevertheless, for locally advanced gastric cancers,
ombined adjuvant chemotherapy and radiotherapy have
ecome a routine consideration at our institution.22,23
In summary, total gastrectomy and esophagectomy with
oux-en-Y reconstruction for Siewert type III cancers is
ssociated with significant morbidity. Nonetheless, long-
erm survival can be achieved with surgical intervention in
small subset of selected patients.
We acknowledge the expert advice and statistical assistance of
s Rachel Gulurud from the Department of Health Sciences
esearch at the Mayo Clinic College of Medicine. We also ac-
nowledge the expert assistance in manuscript preparation of Ms
ristin A. Burke.
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iscussion
r Nasser K. Altorki (New York, NY). This retrospective review
y the Mayo Clinic group probably is one of the largest reported
eries on the surgical treatment of a difficult and largely forgotten
roup of patients, namely those with subcardial cancers invading
he gastroesophageal junction. I say “largely forgotten” because
his particular subset of patients accounted for only 10% of pa-
ients in the Dutch randomized trial for gastric cancer surgery and
or less than 15% of patients in the intergroup gastric cancer
djuvant therapy trial. This is truly an orphan disease. Nobody
ants to claim it. It is not hard to see why that is, having seen the
ata we just saw. Nearly 60% of the patients had transmural
isease; 27% of the patients had disease that encroached on and
nvaded adjacent organs, requiring complex multiorgan resections;
nd 75% of the patients had nodal metastases. Not surprisingly, R0
esections were accomplished in less than 60% of patients, and the
verall survival at 5 years is merely 19%.
We have once again learned from the Mayo Clinic that there
re several factors significantly associated with improved survival,
amely the completeness of the resection and earlier UICC stage
nd earlier T and N status and lower-grade tumor. This series will
e a valuable reference for those of us who continue to treat these
atients from time to time.
I have the following questions for you,
Dr Shen, what criteria were used in this retrospective review to
dentify Siewert type III tumors and distinguish them from massive
idgastric tumors that have extended proximally to engulf the
astroesophageal junction? I am particularly concerned about
hose tumors that required multiorgan resection, such as the kid-
ey, the adrenal, and the ureters, organs that are characteristically
resent low down in the gastric bed.
ber 2006
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TSDr Shen. Thank you, Dr Altorki.
The criteria that were used as inclusion in this patient dataset
as identification of the center of the tumor or the tumor mass
ithin the parameters we discussed for identification of Siewert
ype III tumors. Patients who had linitis plastica or tumors that
nvolved the entire stomach were excluded.
Dr Altorki. How do you distinguish, then, clinically before the
peration between the Siewert type II and type III tumors, and how
oes that influence your operative approach, if at all?
Dr Shen. The preoperative evaluation for almost all of these
atients involves a combination of upper endoscopy, contrast
adiography, and, in the more recent group of patients, endoscopic
ltrasonography and computed tomographic scanning. I think the
perative management for patients with linitis plastica or massive
nvolvement of a tumor in the stomach would be identical; the
pproach would be a total gastrectomy with Roux-en-Y esoph-
gojejunostomy.
Dr Altorki. I would just caution you that sometimes the dis-
inction between a type II and a type III tumor would not be
mmediately apparent using standard preoperative diagnostic cri-
eria, and one thing that you might consider in the distinction
etween them is the use of laparoscopy.
Would you just comment a little bit on the extent of lymph
ode dissection currently advocated for this tumor at the Mayo
linic and your recommendation with respect to adjuvant therapy.
ome have suggested that the value of adjuvant therapy shown in
he intergroup trial is merely correction for a subpar lymph node
issection associated with those operations.
Dr Shen. The median number of lymph nodes that were ex-
mined in the pathologic specimens was 13, with a range of 2 to
6. The median number of positive lymph nodes was 4. A total of
5% of all patients had 15 or more lymph nodes, which is the
urrent recommendation under UICC guidelines for adequate
ymph node dissection.
The practice during this study period at the Mayo Clinic was
ot to formally perform extended lymph node dissection. Never-
heless, I would point out that over the 26-year period analyzed in
his study, the practice did change, in particular with regard to
hether a splenectomy was routinely performed. As you might
magine, with the increase in the incidence of this type of tumor,
here were more patients who underwent surgical intervention
uring the latter 13 years than the first 13 years of the study. Of the
16 patients, 40 were operated on in the first 13 years, and of those,
8 (95%) of 40 had a splenectomy. Conversely, a splenectomy was
nly performed in 50% of the 76 patients in the later group. It was
he practice at Mayo Clinic in the earlier period to routinely
erform a splenectomy as part of the lymphadenectomy, and in
hose patients more lymph nodes were harvested.
Dr Altorki. I have noticed that the 1-year mortality for incom-
letely resected patients was 75%. I wanted to know what your
urrent recommendation is regarding the role of “palliative” re-
ection if an R0 resection cannot be reasonably expected and
egarding the merits of palliative resection in patients with stage
V disease.
Thank you.
Dr Shen. Whether an R0 or R1 resection could be obtained
as, in general, not the determining factor of whether surgical
esection was undertaken. We observed that the vast majority of w
The Journal of Thoracichese patients had important and severe symptoms at the time of
iagnosis. Consequently, a significant proportion, although I can-
ot in retrospect determine the exact proportion, underwent surgi-
al intervention with an a priori palliative objective.
I think one other question that you had asked previously that I
ave not yet addressed was the recommendation for adjuvant
herapy in this group of patients. It is the current feeling of our
roup at Mayo Clinic, as well as most groups in North America,
hat because these patients usually present with such an advanced
tage of disease and long-term survival with surgical resection is as
f yet rather unsatisfying, there might be some evidence that
djuvant therapy provides some long-term survival advantage. The
utch Gastric Cancer Trial Group recently published their pro-
pective, randomized trial investigating extended lymph node dis-
ection in 1000 patients. One of the subgroup analyses evaluated
hether adjuvant therapy was of any benefit. They concluded that
djuvant therapy in this disease is not of any benefit. Nevertheless,
believe that most centers in North America would still recom-
end giving adjuvant therapy.
Dr Altorki. Congratulations on a great presentation.
Dr Shen. Thank you.
Dr Richard Finley (Vancouver, British Columbia, Canada).
gain, that was a wonderful presentation.
I have 3 questions for you. Did you look at complications and
urvival in relationship to the approach? I notice some of the
atients had a laparotomy and some had a thoracotomy. Was there
ny difference in complications and in survival? Did you also look
t the surgeon as a risk factor in your multivariate analysis?
Dr Shen. We did look at survival by the surgical approaches
hat were used. There were 3 approaches: (1) laparotomy only, (2)
ombined thoracoabdominal, and (3) laparotomy followed by tho-
acotomy. There was no difference in terms of long-term survival
n the basis of the approach that was used. We did not look at
pecific complication rates of each surgical approach.
Your second question referred to variation in results by specific
urgeon. We did examine this. As you might imagine, over a
6-year period at Mayo Clinic, there were quite a number of
urgeons involved. Of the 116 patients, there were 24 different
urgeons, although the 3 surgeons with the highest volume ac-
ounted for 53% of the total cases. There was no association or
elationship between surgeon volume in our study and long-term
urvival.
Dr Finley. Second, do you do a frozen section on the esoph-
geal margin? If it is positive, what do you do?
Dr Shen. Yes, frozen sections are done routinely on all re-
ected specimens at Mayo Clinic. If the esophageal margin is
ositive, attempts are made to obtain a clear margin. In some cases
n which a clear esophageal margin was not obtained, either
ntraoperative radiation therapy was given or the patients received
djuvant radiation or chemoradiation.
Dr Finley. Finally, do you use jejunostomies? How do you
upport your patients nutritionally?
Dr Shen. There was also a change in the use of jejunostomy
ubes. Overall, 33 (28%) of the 116 patients had a jejunostomy
ube placed. This was dependent on the era in which the operation
as performed. We bisected the dataset, and in the first 13 years,
nly 1 (2.5%) of the 40 patients had a jejunostomy tube placed,
hereas in the latter half, the more contemporary era, 32 (42%) of
and Cardiovascular Surgery ● Volume 132, Number 4 761
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TS6 had a jejunostomy tube placed. It is the current standard at
ayo Clinic that all patients undergoing this operation undergo
ejunostomy tube placement at the time of the surgical resection
nd receive tube-feed supplementation postoperatively.
Dr Finley. Congratulations on your paper.
Dr Shen. Thank you.
Dr Douglas Mathisen (Boston, Mass). Rob, that was an ex-
ellent presentation.
I believe I saw that there was a 13% incidence of anastomotic
eaks, with a significant contribution to the operative mortality. Do
ou have any sense from looking at these patients how the anas-
omotic leak was handled in this group of patients after a total
astrectomy?
Dr Shen. Yes. The majority of patients who had an anasto-
otic leak were initially managed conservatively. I do not know
he exact number, but in at least a third to a fourth, the patients
ecame quite ill and required reoperation.
Dr Tony Lerut (Leuven, Belgium). This is a very nice study on
very complex and difficult group.
I noticed that you had about 50% strictly transabdominal ap-
roaches versus 50% transthoracic approaches. On what criteria
id you decide to do the approach using laparotomy versus a
ransthoracic access route?
62 The Journal of Thoracic and Cardiovascular Surgery ● OctoDr Shen. It really was the surgeon’s preference as far as which
pproach was used. I think an important factor that went into that
ecision was obviously the preoperative evaluation of how much
f the distal esophagus was involved with tumor in terms of length.
here were other significant preoperative factors that for reasons
f time I did not mention in the presentation but that we discuss in
he manuscript. Eleven percent of all of the 116 patients had prior
astric surgery, most for peptic ulcer disease. There has been an
ssociation in prior studies with patients who have had prior
astric surgery, usually for benign conditions, predisposing them
o gastric cancer. Therefore it was not surprising that 11% of these
atients had prior partial gastrectomies. Therefore that also played
nto the decision of which surgical approach was used.
Dr Lerut. I can imagine that through an abdominal approach it
s more difficult to obtain a sufficient safety margin toward the
roximal extension of the tumor. Was there any difference in the
ncidence of positive margins either at frozen section or final
xamination between the 2 groups (ie, transabdominal vs transtho-
acic)?
Dr Shen. I do not have any data regarding that question. I am
orry.Dr Lerut. Thank you.
ber 2006
Figure E1. Survival (death from any cause) by N status. Zero time
on the abscissa represents the date of surgical resection (P <
.002).
Figure E2. Survival (death from any cause) by tumor grade. Zero
time on the abscissa represents the date of surgical resection. (P
< .02).
Figure E3. Survival (death from any cause) by splenic involve-
ment by tumor. Zero time on the abscissa represents the date of
surgical resection. (P < .008).
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